Ex vivo pravastatin pretreatment experiment recipients | ||||
Blood samples | Healthy + DMEM BMC recipients ( n = 5) | Healthy + pravastatin BMC recipients ( n = 5) | CKD + DMEM BMC recipients ( n = 10) | CKD + pravastatin BMC recipients ( n = 9) |
White blood cells | 5.86 ± 1.20 | 5.52 ± 0.93 | 4.63 ± 1.05 | 5.42 ± 1.18 |
Lymphocytes | 3.30 ± 1.35 | 2.54 ± 0.29 | 2.60 ± 0.86 | 2.94 ± 0.51 |
Midpopulation | 1.58 ± 0.29 | 1.56 ± 0.31 | 1.18 ± 0.28 | 1.59 ± 0.45 |
Granulocytes | 0.98 ± 0.45 | 1.38 ± 0.53 | 0.84 ± 0.35 | 1.08 ± 0.52 |
Red blood cells | 6.66 ± 0.40 | 6.59 ± 0.36 | 6.24 ± 0.59 | 6.63 ± 0.23 |
Hemoglobin | 8.06 ± 0.47 | 7.90 ± 0.42 | 7.63 ± 0.72 | 7.86 ± 0.29 |
Hematocrit | 0.33 ± 0.05 | 0.33 ± 0.019 | 0.31 ± 0.029 | 0.33 ± 0.010 |
Mcv | 49.08 ± 0.83 | 50.08 ± 1.08 | 50.10 ± 2.09 | 49.35 ± 0.78 |
Mchc | 24.38 ± 0.22 | 23.94 ± 0.38 | 24.18 ± 0.43 | 24.08 ± 0.36 |
Rdw | 15.44 ± 0.43 | 15.22 ± 0.29 | 15.63 ± 1.125 | 15.151 ± 0.818 |
Platelets | 736 ± 68 | 697 ± 49 | 634 ± 99 | 699 ± 55 |
Systemic in vivo pravastatin treatment | ||||
Blood samples | CKD (n = 6) | CKD + pravastatin ( n = 5) | Â | Â |
White blood cells | 4.81 ± 0.89 | 4.50 ± 1.16 |  |  |
Lymphocytes | 2.87 ± 0.59 | 2.90 ± 0.97 |  |  |
Midpopulation | 1.27 ± 0.39 | 0.90 ± 0.19 |  |  |
Granulocytes | 0.65 ± 0.16 | 0.68 ± 0.13 |  |  |
Red blood cells | 6.38 ± 0.22 | 6.25 ± 0.15 |  |  |
Hemoglobin | 7.58 ± 0.32 | 7.52 ± 0.18 |  |  |
Hematocrit | 0.32 ± 0.01 | 0.31 ± 0.01 |  |  |
Mcv | 49.37 ± 0.79 | 49.96 ± 0.32 |  |  |
Mchc | 24.05 ± 0.25 | 24.14 ± 0.23 |  |  |
Rdw | 15.13 ± 0.63 | 15.14 ± 0.68 |  |  |
Platelets | 681 ± 42 | 666 ± 41 |  |  |